Harvard Medical School Professor John Yeh Visit WorldPath Clinic International
During the visit, Dr. Yeh shared the most cutting edge technologies and knowledge of OB/GYN fields in the US and discussed with physicians from WorldPath Clinic International about related diagnostic and treatment approaches for Chinese patients.
John Yeh, MD
Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
Dr. Yeh, a physician scientist, has made a significant impact in the field of obstetrics and gynecology through publishing significant translational research results in ovarian research; publishing important analysis of statistical, clinical information regarding outcomes in pregnancy related to pre-pregnancy obesity; directing a productive research group; training investigators and academic leaders through his research laboratory; providing leadership and academic talks to academic and professional organizations, and; engaging in initiatives to improve maternal clinical care through national and international organizations and grant review.
Through his academic and professional involvements, Dr. Yeh has become a well recognized and respected international leader in the field of Obstetrics and Gynecology and Reproductive Endocrinology. As evidence of his outstanding reputation in Obstetrics and Gynecology, Dr. Yeh received the "Distinguished Service Award" from the American College of Obstetricians and Gynecologists (ACOG) at the organization's annual meeting in 2009, which is one of the highest recognitions in the field of Obstetrics and Gynecology.
Dr. Yeh regularly presents talks on his areas of Reproductive Endocrinology, including ovarian function, hirsutism and ovarian reserve. Most recently, he addressed the specific subject of ovarian reserve preservation after chemotherapy at a talk in 2008 to the Division of Reproductive Endocrinology and Infertility at the Brigham and Women's Hospital and in 2009 at Capital Medical University School of Basic Medical Sciences in Beijing, China. Since his year service to the United States Agency for International Development, he has begun introducing the topics of maternal mortality and the challenges of obstetrical fistula into his speaking engagements. He has lectured in the United States and in Taiwan, Korea, China, Turkey, and Africa. Examples of these talks include: 2005, 2006, 2007, 2008, American College of Obstetrics and Gynecologists, Annual Meeting, Hirsutism, Invited Roundtable Speaker; 2008, Ovarian Function after Chemotherapy, Brigham and Women's Hospital, Reproductive Endocrinology and Infertility Seminar; 2008, Maternal Mortality, Grand Rounds, Brigham and Women's Hospital and Georgetown University; 2007, Ovarian Function, Istanbul University, Istanbul Society of Medicine, Istanbul, Turkey; 2008, Obstetrical Fistula Research, USAID Fistula Partners' Meeting, Accra, Ghana, when with USAID; and, 2009, Ovarian Function After Chemotherapy, Capital Medical University School of Basic Medical Sciences, Beijing, China.
Dr. Yeh has served on numerous United States Obstetrics and Gynecology committees in a number of important roles, including Scientific Program Committee Co-Chair for ACOG District II; Scientific Program Committee ACOG; Oral Examiner for the American Board of Obstetrics and Gynecology; and ACOG umbilical cord blood committee. The committee service and service as an Oral Examiner are reserved for the most widely recognized and respected authorities in the specialty of Obstetrics and Gynecology.
Dr. Yeh was selected by the U.S. National Academies to serve as a Jefferson Science Fellow and Senior Science Advisor with the U.S. Department of State from 2007-2008. While doing so, he continued to provide leadership to the department in Buffalo as the Chair of Gynecology-Obstetrics. As the first physician-scientist to serve as a Jefferson Fellow, he worked in the Global Health Bureau of the U.S. Agency for International Development (USAID), concentrating on strengthening policies and programs in maternal and child health to increase collaboration between USAID, individual countries, and international organizations, to develop practices designed to improve maternal mortality and health rates, and to develop health system infrastructures. In one year with USAID, he visited numerous countries, including Ghana, Bangladesh, Nepal and Tanzania. With an additional focus on U.S. government interagency cooperation, he served on advisory committees intended to expand joint efforts in science, research, and education.
Dr. Yeh has been a reviewer for numerous journals and grant-making organizations. He has also been asked to serve on study sections at the NIH, such on the service in 2010 on the Study Section for Chemoprotection, service as a consultant at WHO for Obstetrical Hemorrhage, service as a consultant for Fistula Care, which is a Congressional funded program to address the clinical problem of Obstetrical Fistulas. In addition, he was asked to serve as an outside reviewer for the Pennsylvania State University Department of Obstetrics and Gynecology. He served on the editorial board of Clinical Updates in Women's Health Care and other journals related to his field of expertise. All these invitation substantiate the national and international reputation Dr. Yeh has in the field of Obstetrics and Gynecology.
Dr. Yeh has authored or coauthored over 100 peer-reviewed articles, review articles and conference proceedings. Dr. Yeh is an innovative and prolific researcher and author in the field of obstetrics, gynecology and reproductive biology. The two areas in which he has published important papers are in the area of ovarian biology and in the area of clinical obstetrics and gynecology.
His research investigation has been in translational research as it relates to ovarian function, specifically ovarian reproductive aging and chemotherapy-induced ovarian damage.
The findings from Dr. Yeh's laboratory investigations have led to new ideas about how to develop biomarkers for ovarian aging and for protection against chemotherapy induced ovarian damage.
Significant works that he has published in this area include: Yeh J, Kim B, Liang YJ, Peresie J: Mullerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage. Biochem Biophy Res Comm 348(2): 337-344, 2006. Significance of paper: This paper is the first to show that mullerian inhibiting substance can serve as a serum biomarker marker of ovarian damage from chemotherapy in a rat model. It provides the best model for measuring the degree of ovarian damage from chemotherapeutic agents. Yeh J, Kim B: Increasing blunting of inhibin responses to dynamic ovarian challenge is associated with reproductive aging in the rat. Reproductive Sciences 14(1): 10-19, 2007. Significance of paper: This paper demonstrated that with reproductive aging, the serum biomarkers of ovarian function, inhibin A and inhibin B, have increasing blunting of responses to ovarian challenge testing. This provided evidence in an animal model that ovarian challenge testing to amplify the differences in decreases in ovarian reserve (an important determinant of the follow up algorithms for infertility patients) during aging is a useful tool. Yeh J, Kim B, Peresie J, Liang YJ, Arroyo A: Serum and ovarian mullerian inhibiting substance, and their decline in reproductive aging. Fertil Steril 87(5): 1227-1230, 2007. Significance of paper: This paper was the first to show that serum mullerian inhibiting substance (MIS) is the most sensitive biomarker of ovarian aging in a rat model. The paper demonstrated that the serum level of MIS is a direct reflection of the number of small follicles in the ovary expressing MIS. This paper provided histologic data supporting human clinical care using an indirect method, ultrasonography, in everyday infertility patient care. Yeh J, Kim BS, Peresie J: Protection against cisplatin-induced ovarian damage by the antioxidant sodium 2 mercaptoethanesulfonate (mesna) in female rats. Am J Obstet Gynecol 198:463-465, 2008. Significance of paper: This paper provided for the first time evidence that a drug could be used to protect against the ovarian damage from cisplatin, a chemotherapeutic agent. The findings provide animal model support for the novel approach of using an antioxidant as a protective agent in protecting the ovary during cancer therapy. Yeh J, Kim B, Liang YJ, Peresie J: Gonadotropin stimulation as a challenge to calibrate cisplatin induced ovarian damage in the female rat. Reprod Toxicol 28(4): 556–562, 2009. Significance of paper: This paper provided evidence that ovarian challenge is useful in defining the degree of ovarian damage from chemotherapeutic agents. This information allows the creation of additional opportunities to define human ovarian reserve after chemotherapy.
Thus, the impact of Dr. Yeh's laboratory investigation is the creation of an important animal model for understanding how chemotherapy affects ovarian function and novel approaches that may be taken to protect the ovary from damage. Furthermore, his investigations of reproductive aging have shown that in animal models, the biomarkers useful in human clinical care have a histological basis.
In addition, Dr. Yeh has contributed substantially to the understanding of issues pertaining to the delivery of clinical care in the area of Obstetrics and Gynecology. He has published a number of important papers pertaining to gestation outcomes in relation to prepregnancy body mass index and weight gain, including the following: Yeh J, Shelton JA: Increasing prepregnancy body mass index: analysis of trends and contributing variables. Am J Obstet Gynecol 193:1994-1998, 2005. Yeh J, Shelton JA: Association of prepregnancy maternal weight and maternal weight gain to newborn outcomes in twin pregnancies. Acta Obstet Gynecol Scand 86: 1051-1057, 2007. Eddib A, Penvose-Yi J, Shelton JA, Yeh J: Triplet gestation outcomes in relation to maternal prepregnancy body mass index and weight gain. J Matern Fetal Neonatal Med 20(7): 515-519, 2007.
These papers were the first to address weight gain in the multiple gestations.
Furthermore, Dr. Yeh has addressed these following: Yeh J, Wactawski-Wende J, Shelton JA, Reschke J: Temporal trends in the rates of trial of labor in low-risk pregnancies and their impact on the rates and success of vaginal birth after cesarean delivery. Ogunleye O, Shelton J, Ireland A, Glick M, Yeh J: Preferences for labor and delivery practices between pregnant immigrants and US-born patients: a comparative prospective antenatal survey study. J Natl Med Assoc 102(6): 481-484, 2010
The impact of the clinical papers is the better understanding of pregnancy and clinical issues related to pregnancy, including population studies and issues related to cultural needs of pregnant women.
Dr. Yeh has been actively engaged in teaching his entire professional career. At the Beth Israel Deaconess Medical Center and Harvard Medical School, he oversaw the core clerkship for one third of the Harvard Medical School third year medical students, the nationally renowned residency in Obstetrics and Gynecology and fellowships in Reproductive Endocrinology and Maternal Fetal Medicine. In addition, he oversaw the creation of a joint fellowship in Urogynecology with the Mount Auburn Hospital. From 2000-2009, he served as Program Director for the Obstetrics and Gynecology Program at the University at Buffalo, one of the largest training programs in Obstetrics and Gynecology in New York State, with 36 residents in the program. During that time, he was responsible for several key recruitments and oversaw the establishment and approval of a new post-graduate fellowship. As a testament to the excellence of his teaching, he received an Excellence in Teaching Award from the Association of Professors of Gynecology and Obstetrics as well as an Outstanding Professor Award from the American College of Obstetricians and Gynecologists, District II.
Nationally, he has served in several important capacities regarding residency education in Obstetrics and Gynecology. He has served on the test writing committee for the inservice examination, an important activity directed to evaluating the performance of trainees in Obstetrics and Gynecology. In addition, he has served on the Education Committee of Council on Residency Education in Obstetrics and Gynecology (CREOG), a key US national obstetrics and gynecology residency committee charged with designing national residency curricula. He was actively involved with the development of the latest version of the required curriculum for all residency programs in Obstetrics and Gynecology in the United States.
In addition, Dr. Yeh has directly trained over 40 medical students, residents, and fellows in his research group. These trainees are established throughout the country in academic institutions such as Harvard, the University of California at San Francisco, the University of Chicago, as well as Canada and Asia. A number of these trainees hold senior academic ranks, including a former postdoctoral fellow who was appointed Dean of his medical school in Korea.
Dr. Yeh has served in senior administrative positions in Obstetrics and Gynecology for many years. From 2009 until the present, he serves as the Chair of the Department of Obstetrics and Gynecology at the Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Yeh distinguished himself in his 2000-2009 tenure as Professor and Chair of the Department of Gynecology-Obstetrics at the State University of New York's University at Buffalo's School of Medicine and Biomedical Sciences. At Buffalo, he rejuvenated and energized a department that had a history greater than 150 years. In addition to his academic and national involvement and leadership of the Buffalo department, Dr. Yeh made significant contributions to the University at Buffalo on a university-wide basis. After a competitive selection process, he participated in the University at Buffalo's Faculty in Leadership program in 2005-2006, where he actively worked to create a university wide office to serve the post-doctoral fellows at the university. In addition, he served on numerous university-wide committees, including the selection committee for the University's Vice-President for Health Sciences, chair representative for the Board of the University at Buffalo Faculty Practice Plan and the SUNY Honorary Degree Committee. At BIDMC, he oversaw the creation of a new division of Urogynecology and the performance of the first gynecologic robotic surgery. He helped to maintain and advance the culture of patient safety within the BIDMC department. In addition, he oversaw a three-fold increase of NIH funding in the BIDMC department and the creation of the infrastructure for cutting edge research in Obstetrics and Gynecology.